Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70

Xiaosheng Fang¹, Yujie Jiang¹, Lili Feng¹, Haiping Chen³, Changqing Zhen¹, Mei Ding¹ and Xin Wang¹,²*

Abstract
Up-regulation of heat shock protein 70 (HSP70) could be elicited primarily by heat in former studies, and this was proved to be associated with cancer progression. Burkitt’s lymphoma is one of highly aggressive B-cell non-Hodgkin’s lymphoma and is one of the fastest growing human tumors. To investigate the effect of HSP70 expression on the sensitivity of human Burkitt lymphoma cells (Raji cells) to chemotherapy and its role in the involvement of PI3K/AKT pathway, we evaluated the effects of LY294002, a PI3K inhibitor, on the expression of HSP70 and cell sensitivity to adriamycin (ADM) or cisplatin (DDP). In present study, expressions of HSP70, AKT and phosphorylated AKT (p-AKT) in Raji cells were measured by Western-Blot. Apoptosis index of Raji cells was examined by flow cytometry. Cytotoxicities of adriamycin (ADM) and cisplatin (DDP) were determined by WST-8 assay. We found that hyperthermia (42 degrees for 1 hour) up-regulated the expression of HSP70 expression and blockade of PI3K/AKT pathway down-regulated HSP70 expression in Raji cells. Compared to cells treated with ADM or DDP alone, hyperthermia protected cells from chemotherapy while LY294002 enhanced sensitivity of Raji cells to chemotherapy. Our results suggested down-regulation of HSP70 expression by blockade of PI3K/AKT pathway maybe responsible for the increased sensitivity of Raji cells to chemotherapy. Targeting PI3K/AKT pathway or inhibiting HSP70 expression may be beneficial for chemotherapy treatment of Burkitt lymphoma patients.

Keywords: Raji, Hyperthermia, HSP70, PI3K/AKT

Introduction
Burkitt lymphoma (BL) is an aggressive, highly proliferative lymphoma, in spite of its low incidence throughout most of the world [1]. It can often be cured by intensive chemotherapy, but the toxicity of such therapy precludes its use in the elderly and in patients with endemic BL in developing countries [2]. Novel therapeutic strategies are required to overcome drug toxicity following conventional treatments.

HSP70 is an important cellular chaperone. Its expression is induced by a wide variety of physiological and environmental insults and allows the cells to survive lethal conditions [3,4]. HSP70 is over-expressed in various human cancers, including pancreatic cancer [5], bladder cancer [6], colon cancer [7], breast cancer [8] and non-Hodgkin’s lymphoma [9]. In cancer cells, over-expression of HSP70 is thought to provide a survival advantage because it is able to interact with multiple components of both the caspase dependent and independent apoptotic pathways [10]. The expression of HSP70 has been routinely associated with cancer progression, therapy responses and poor prognosis in multiple forms of cancers [11,12] and it can be used as a novel biomarker for early detection of cancers. HSP70 also has emerging as a therapy target in cancers recently. Gene silencing of HSP70 inhibits human cancer cell growth in vitro and in vivo [13] and leads to loss of invasion in a variety of cancer cells [14].

Activation of heat shock factor 1 (HSF1) is the key step in the induction of HSP70 expression. HSF1 exists as an inactive monomer in a complex with HSP40/HSP70 and HSP90. In such stress as elevated temperature, HSF1 is released from the chaperone complex and transported into the nucleus where it is hyperphosphorylated and...
binds to DNA containing heat shock elements (NGAAN), leading to rapid induction of these important molecular chaperones [3]. Recently, studies revealed the abolishment of serine473 phosphorylation in Akt could significantly reduce its kinase activity in CML cells. Inactivation of Akt pathway subsequently blocked serine9 phosphorylation of Gsk3β. Active non-phosphorylated Gsk3β rendered HSF1 transcriptionally inactive and reduced HSP70 production. And blocking PI3K/Akt activity also be demonstrated could induce the similar effects on HSP70 expression [15].

Given the role of HSP70 in tumors and the involvement of PI3K/Akt activity in HSP70 expression, it is reasonably plausible that blockade of PI3K/Akt pathway may affect HSP70 production and then up-regulate chemotherapy sensitivity in tumor cells. In present study, we demonstrated that hyperthermia treatment (HT) induced HSP70 expression was mediated by PI3K/Akt pathway in Raji cells. Furthermore, blocking of PI3K/Akt pathway could down-regulate HSP70 expression, inhibit cancer cells survival and promote cells apoptosis when co-treated with ADM or DDP. The decrease of HSP70 expression maybe at least partially responsible for the increased chemotherapy sensitivity of Raji cells. Targeting PI3K/Akt pathway may provide new method to improve chemotherapy effects in cancer patients.

Materials and methods

Chemicals

LY294002, a PI3K inhibitor (CST,Danvers, MA, USA), was dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA) and stored at -20°C. The stock concentration was 10 mmol/L and the final concentration of DMSO in medium did not exceed 0.05%. At this level, DMSO did not influence cell viability. Adriamycin (ADM) was purchased from Shanghai Pharma, China and cis-platin (DDP) was obtained from Qilu Pharmaceutical co., LTD, Shandong, China. They were dissolved in deionized water to a concentration of 1.0 mg/ml, and then were diluted to defined concentrations for further experiment.

Cell culture

Raji cells were purchased from Shanghai Institutes for Biological Sciences (SIBS, CAS, Shanghai, China) and maintained in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) containing 10% heat-inactivated fetal bovine serum albumin (Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, Zhejiang, China), penicillin (100 U/ml), and streptomycin (100 mg/ml) in the 95% humidified incubator with 5% CO₂ at 37°C. To explore the effects of HT on cell growth and HSP70 expression, Raji cells were seeded on coverslips in 24-well microplates and cultured at 42.0°C for 1 hour, and then immediately returned to 37.0°C for continuous incubation of 2, 4, 8 or 24 hours. To analyze the effects of LY294002 on cell growth and expression of HSP70, Raji cells were cultured with or without LY294002 (5 μM, 10 μM, 20 μM, 40 μM) for 8 h. For experiments with ADM or DDP treatment, Raji cells were treated with LY294002 or HT (42.0°C for 1 hour) before being exposed to chemicals. Cells were then received continuous incubation of 8 hours at 37.0°C. At last, cells were collected for apoptosis assay and immunoblot analysis of HSP70.

Flow cytometric analysis

After treatment of Raji cells with LY294002 / HT, or together with ADM or DDP for the indicated periods, Annexin V/PI staining was analyzed by FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). The measurement of protein concentrations and detailed procedures of immunoblot analysis were described previously [16].

Assessment of cell viability

After received LY294002 or hyperthermia treatment as described previously, cells (1 × 10⁵) were seeded into 96-well plates. ADM and DDP were then added into cultures. Twenty-four hours later, 10 μL CCK-8 (Dojindo Molecular Technologies, Kumamoto, Japan) was added to each well, and the cells were incubated at atmosphere for 4 hours. The absorbance at 450 nm was then measured using a microplate reader. Percentage of survival cell was calculated as follows: (Aexp group-Ablank/Acontrol-Ablank) × 100%.

Statistics

Analyses of data were performed by using SPSS15.0 for Windows. Data are presented as the mean ± SD. Differences in the results for two groups were evaluated by Student's t-test. Half maximal inhibitory concentration (IC₅₀) was analyzed with the linear regression. All experiments were repeated at least three times. All differences were considered to be statistically significant when the P value was less than 0.05.
Results

Effects of HT and LY294002 on cell apoptosis and expression of HSP70

Raji cells were used for the present study. We found that the apoptosis rate of cells in HT treated cells was similar to that in cells without HT treatment (data was not shown). However, HSP70 expression was enhanced obviously by exposure of HT and increased in a time-dependent manner in the first 8 hours. After 24 hours, the expression of HSP70 was still significantly higher than untreated controls (P < 0.05) (Figure 1A).

LY294002, a PI3K inhibitor, was used to block PI3K/AKT pathway. In order to explore the apoptosis-inducing effect of LY294002 on Raji cells, we detected the apoptosis rate of Raji cells after treatment with LY294002. As shown in Figure 1B, there was no difference in control group and LY294002 group when its concentration was at 5 μM, 10 μM, and 20 μM. However, LY294002 at 40 μM could increase apoptosis rate obviously. In our following experiment, we used 20 μM of LY294002 to analyze its effect on expression of HSP70 and p-AKT in Raji cells. We found that HT could significantly upregulate the expression of HSP70 and p-AKT expression obviously while LY294002 (20 μM) could inhibit their expression dramatically (P < 0.05) (Figure 1C). These results showed that expression of HSP70 and activation of AKT (p-AKT) were attenuated significantly by LY294002 at the concentrations of 20 μM.

DDP induced apoptosis was protected by HT and promoted by LY294002

To determine whether PI3K/AKT pathway and HSP70 protein expression were involved in the cancer cell sensitivity to chemotherapy, cells were incubated with LY294002 (20 μM) or HT treatment (42.0°C for 1 hour) before they were exposed to chemicals. As shown in Figure 1A, 42.0°C was enough to induce the expression of HSP70. In addition, 20 μM of LY294002 could inhibit HSP70 expression dramatically and has no effect on Raji cells apoptosis. DDP at different concentrations was added into the medium of Raji cells, HT treated cells and LY294002 treated cells. After incubated with DDP for 8 hours, cells were collected and cell apoptosis index was analyzed by flow cytometry (Figure 2). We showed that cell apoptosis was induced by DDP in a concentration-dependent manner in DDP group (14.1 ± 0.5% at 5 μg/ml, 16.9 ± 1.14% at 10 μg/ml, P < 0.01) (Figure 2A, B), while the apoptotic cells in HT + DDP group was not increased with the increasing of DDP concentration (9.73 ± 0.28% at 5 μg/ml, 10.50 ± 0.85% at 10 μg/ml, P > 0.05) (Figure 2C, D). In

![Figure 1](http://www.cancerci.com/content/13/1/48)
LY294002 + DDP treated group, the apoptosis rates of Raji cells were 25.2 ± 0.42% and 31.5 ± 0.37% respectively when the concentration of DDP were 5 μg/ml and 10 μg/ml (Figure 2E, F). Furthermore, when DDP concentration was equal, the apoptosis rate in LY294002 + DDP group was significantly higher than DDP group and the percentage of
apoptotic cells in HT + DDP group was significantly lower than DDP group (P < 0.05). These results indicated that HT contributed to chemotheapeutic tolerance of Raji cells, while LY294002 promoted DDP induced cell apoptosis.

HT protected Raji cells from chemotherapy while LY294002 enhanced their sensitivity to chemotherapy

Besides the effects of HT and LY294002 on cell apoptosis, other mechanisms in cell growth caused by HT and LY294002 were also explored. We next examined cell survival by WST-8 assay. As shown in Figure 3A, cell viability were inhibited by ADM in a concentration-dependent manner. Raji cells in HT + ADM group showed more resistant to ADM than ADM group and IC50 increased from 4.5 μg/ml to 15.9 μg/ml. When treated with LY294002 and ADM, Raji cells were more sensitive to ADM and the IC50 was 3.6 μg/ml. Similar phenomenon was also observed when Raji cells were treated with DDP. The IC50 in DDP group, HT + DDP group and LY294002 + DDP group were 5.2 μg/ml, 10.1 μg/ml and 2.6 μg/ml respectively (P < 0.05) (Figure 3B).

Discussion

In this study, we observed that hyperthermia activated the expression of HSP70 in Raji cells. High expression of HSP70 was associated with lower apoptosis rate and resistance to chemotherapy drugs. Blockade of PI3K/AKT pathway not only inhibited HSP70 expression, but also contributed to chemotherapy sensitivity of Raji cells. Our findings suggested targeting PI3K/AKT/HSP70 pathway may decrease chemotherapy drugs dosage and overcome drugs resistance in Raji cells.

HSP70, one of the most important members of HSPs family, its up-regulation is known to occur as a part of the cellular defense system against environmental stresses such as heat shock, oxidative stress, or treatments with chemical agents. Previous studies indicated that Hsp70 played an important role in the control of cell cycling and growth. Up-regulation of HSP70 also has been shown to contribute to cancer cell survival via multiple anti-apoptotic functions [17]. HSP70 inhibits p53 [18] at the premitochondrial level [19], prevents mitochondrial outer membrane permeabilization (MOMP) by blocking BAX translocation and inhibit the release of cytochrome at the mitochondrial level [20,21], blocks the recruitment of procaspases 9 and 3 to the apoptosome complex, and the assembly of functional apoptosome at the postmitochondrial stage [22]. It also inhibits the activation of AIF and JNK, which induce apoptosis in a caspases-independent way [23,24]. These findings indicated a distinct and extensive anti-apoptotic function of HSP70.

Accumulating evidences indicated that hyperthermia induced HSP70 expression was related with chemotherapy resistance [25]. Moreover, Behnsawy et al had proved that the expression of HSP70 was correlated with cell survival when treated with chemotherapy [26]. In acute myeloid leukemia and acute lymphoblastic leukemia, HSP70 is an indicator for poor prognosis [27]. However, the precise mechanism of Hsp70 in lymphoma cell survival and chemotherapy resistance remains unclear. In the study, we demonstrated that hyperthermia induced HSP70 expression and protected Raji cells against ADM and DDP treatment.

The induction of HSP70 in response to various stimuli is mainly regulated by the activation of HSF1 [28]. Recent studies have showed that PI3K/AKT signal pathway was involved in the induction of HSP70 expression [29,30]. This regulation might rely on the fact that the activation of AKT inhibited GSK-3β [31], and the inhibition of GSK-3β could activate HSF1. In our study, we blocked
PI3K/AKT signaling pathway by LY294002 and detected the altered expression of HSP70 in Raji cells. Our results indicated the blockade of PI3K/AKT signaling pathway inhibited HSP70 expression obviously. However, some studies demonstrated that these signal cascades were not found in either lens endothelial cells nor U937 cells under certain conditions [32,33]. These contradictory phenomena might be incriminated to cell heterogeneity as well as different disposal conditions.

PI3K/Akt signaling pathway is frequently activated in malignant diseases, including many hematologic malignancies [34] and contributes to tumor cell survival [35-38]. The up-regulation of this signal pathway was also suggested to increase drug resistance [39], but the underlying mechanism is not fully proved. In this study, we confirmed the existence of PI3K/AKT/HSP70 pathway in Raji cells. Blockade of PI3K/AKT pathway not only inhibit HSP70 expression, but also promote cell sensitivity to chemotherapy. Given the relationship between HSP70 expression and chemotherapy resistance, we concluded that down-regulation of HSP70 was at least partly responsible for the promotion of Raji cells sensitivity to chemotherapy. Inhibition of HSP70 may be an encouraging method to overcome chemotherapy resistance.

Antisense HSP70 oligomer and HSP70 siRNA have been used to induce low expression of HSP70 in different kinds of cells and resulted higher apoptosis rate [40,41]. However, there are still some problems in their clinical application. Quercetin, a kind of flavanoid, inhibited HSPs expression in many kinds of cancer cells [42,43]. Cells became more susceptible to apoptosis when treated with quercetin followed by hyperthermia, chemotherapy or radiotherapy [44-46]. But quercetin showed significant toxicity even used as a signal agent, which largely limited its clinical application. HSP90, another important member of HSPs family, is closely related with cancer treatment. One of its specific inhibitor, 17-allylamino-demethoxy-geldanamycin (17-AAG), had been presented in the completed stage I clinical trial and demonstrated a favorable therapeutic effect. Another inhibitor PU-H71 has demonstrated considerable anti-tumor activity in diffused large B cell lymphoma and multiple myeloma [47]. So far there is no specific small-molecule HSP70 inhibitor which is available comparable with 17-AAG.

In summary, we documented that PI3K/AKT/HSP70 pathway existed in Raji cells and revealed an intriguing mechanism that down-regulation of HSP70 was responsible for the promotion of sensitivity to chemotherapy in Raji cells. Targeting PI3K/AKT pathway or inhibiting HSP70 expression may be an encouraging method to overcome chemotherapeutic resistance.

Competing interest
The authors have no relevant conflicts of interest.

Authors’ contributions
XW designed research. XF, YJ and LF performed research. HC was responsible for statistical analysis. CZ drafted the manuscript. MD revised it critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements
This study was partly supported by: National Natural Science Foundation (No. 81270598), Natural Science Foundations of Shandong Province (No. Y2007C053, No. 2009ZRB14176 and No. ZR2012HQ003), Technology Development Projects of Shandong Province (No. 2007GG10, and No. 3105GF10250), Program of Shandong Medical Leading Talent, and Taishan Scholar Foundation of Shandong Province.

Author details
1. Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, P.R. China. 2. Department of Diagnostics, Shandong University School of Medicine, Jinan 250021, P.R. China. 3. Department of Cardiology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, P.R. China.

Received: 26 March 2013 Accepted: 10 May 2013 Published: 24 May 2013

References
1. Spender LC, Inman GJ. Phosphoinositide-3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt’s Lymphoma cells to BTH3-mimetics. Mol Cancer Res 2012, 10:347–359.
2. Smirnitz R, Young RM, Cerbelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Bhatia E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116–120.
3. Gong TW, Fairfield DA, Fullarton L, Dolan DF, Atschieler RA, Kohnman DC, Lomax MI. Induction of heat shock proteins by hyperthermia and noise overstimulation in hsf1 (−/−) mice. JACR 2012, 13:25–37.
4. Rérole AL, Jego G, Garrido C. Hsp70: Anti-apoptotic and Tumorigenic Protein. Methods Mol Biol 2011, 787:205–230.
5. Dutta SK, Girotta M, Singlea M, Dutta A, Orts Stephen F, Nair PP, Merchant NB. Serum HSP70: A Novel Biomarker for Early Detection of Pancreatic Cancer. Pancreas 2012, 41:530–534.
6. Margel D, Pevsner-Fischer M, Daniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol 2010, 59:113–119.
7. Bauer K, Nitsche U, Slotta-Huspenina J, Drecoll E, von Weyhern CH, Rosenberg R, Höfler H, Langer R. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. Cell Oncol (Dordr) 2012, 35:197–205.
8. Kolongiakita A, Giannikaki E, Tzardis M, Kafousi M, Ieromonachou P, Darivianaki K, Askoxylakis I, Tufis T, Statopoulos E, Zoras O. Correlation of heat shock protein (HSP70) expression with cell proliferation (MIB1), estrogen receptors (ER) and clinicopathological variables in invasive ductal breast carcinomas. J Exp Clin Cancer Res 2007, 26:367–368.
9. Fang X, Liu X, Wang X. Expression of HSP70 , 90a in NHL and its clinical significance. Journal of Shandong University (Health Science) 2009, 47:43–46.
10. Mosser DD, Morimoto R. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907–2918.
11. Yang X, Wang J, Zhou Y, Wang Y, Wang S, Zhang W. HSP70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Letters 2012, 321:137–143.
12. Evans CG, Chang L, Gentzki J. Heat Shock Protein 70 (Hsp70) as an Emerging Drug Target. J Med Chem 2010, 53:4585–4602.
13. Zhong MA, Zhang H, Qi XY, Lu AG, You TG, Gao W, Guo XL, Zhou ZQ, Yang Y, Wang CJ. SHRNA-mediated gene silencing of heat shock protein 70 inhibits human colon cancer cell growth in vitro and in vivo. Mol Med Rep 2011, 4:805–810.
14. Teng Y, Ngoka L, Mei Y, Leson L, Cowell J: HSPP90 and HSPP70 are essential for stabilization and activation of the WASF3 metastasis promoting protein. J Biol Chem 2012, 287:10051–10059.

15. Sun J, Conn CS, Han Y, Yeung V, Qian SB: PI3K-mTORC1 attenuates stress response by inhibiting cap-independent HSPP70 translation. J Biol Chem 2011, 286:4971–4982.

16. Feng L, Guo JM, Li PP, Wang X: IL-9 contributes to Immunosuppression Mediated by Regulatory T Cells and Mast Cells in B-Cell Non-Hodgkin's Lymphoma. J Clin Immunol 2011, 31:1084–1094.

17. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matasova N, Francis GL, Graham CJ, Parsons R, Wang Y, Padfield A, Comer M, Drysdale MJ, Wood M: A novel, small molecule inhibitor of Hsp70/70 potentiates HSPP90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010, 65:39–45.

18. Gabai VL, Yaglom JA, Waldman T, Sherman MY: Fang http://www.cancerci.com/content/13/1/48.

19. Lee KH, Jeong J, Yoo CG: Heat-shock proteins in infection-mediated preconditioning hinders thrombosis by reinforcing phosphatidylinositol glycogen synthase kinase-3 β-dependent multiple myeloma. J Hematol Oncol 2011, 286:4013–4020.

20. Bivik C, Rosdahl I, Ollinger K: PI3K/Akt-mediated Hsp70 expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol 2012, 5:16.

21. Plastaras JP, Dorsey JF, Carroll K, Kim SH, Bimbaum JS, El-Deiry WS: Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 2008, 7;2007–2053.

22. Zollinger A, Stürmer T, Chatterjee M, Gattenlöchner S, Haralambiev E, Müller-Hermelink HK, Andrulis M, Greiner A, Weseimeier C, Rath JC, Eisene H, Bargou RC: Combined functional and molecular analysis of tumor cell signaling defines distinct myeloma subgroups: Akt-dependent and Akt independent multiple myeloma. Blood 2008, 112:3403–3411.

23. Ikeda H, Hideshima T, Fulcrini M, Perrone G, Miura N, Fusa H, Okawa Y, Kiziltepe T, Santo L, Valti S, Cirstea D, Cabalres E, Gorgun G, Rajh NS, Richardson P, Munshi NC, Lannutti BJ, Pur XD, Giese NA, Anderson KC: PI3K/p110(delta) is a novel therapeutic target in multiple myeloma. Blood 2011, 116:1460–1468.

24. Peng DJ, Wang J, Zhou JY, Wu GS: Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010, 394:600–605.

25. Xia LM, Tian DA, Zhang Q, Yan W, Wang B, Liu M, Li PY, Chen B: Inhibition of HSPP70-2 expression by RNA interference induces apoptosis of human hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi 2008, 16:678–682.

26. Liu W, Chen Y, Lu Q, Sun L, Si J: Down-regulation of HSPP70 sensitizes gastric epithelial cells to apoptosis and growth retardation triggered by H2pylen. BMC Gastroenterol 2011, 11:146.

27. Shen J, Zhang W, Wu J, Zhu Y: The synergistic reversion effect of multitarget resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Int J Hyperthermia 2008, 24:151–159.

28. Russo A, Cardile V, Gaggia S, Gunther G, Troncoso N, Garbarino J: Boldo prevents UV light and nitric oxide-mediated plasmid DNA damage and reduces the expression of HSPP70 protein in melanoma cancer cells. J Pharm Pharmacol 2011, 63:1219–1229.

29. Sahin E, Sahin M, Sanlioglu AD, Gumuslu S: KNK437, a benzylidene lactam compound, sensitizes prostate cancer cells to the apoptotic effect of hyperthermia. Int J Hyperthermia 2011, 27:63–73.

30. Wachsberger PR, Burd R, Bhal A, Bobooyek SB, Wahl ML, Owen CS, Rifat SB, Leeper DB: Quercetin sensitizes cells in a tumor-like low PH environment to hyperthermia. Int J Hyperthermia 2003, 19:507–519.

31. Hu W, Wu W, Verschaeren CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ: Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by famesul transferase inhibitor. Proteomics 2003, 3:11904–11911.

32. Usman S, Borna RD, Chossi G, Li Z: The anti-myeloma activity of a novel purine scaffold HSPP90 inhibitor PU-H71 is via inhibition of both HSPP90A and HSPP90B1. J Hematol Oncol 2010, 3:40.